

Caitlin Gillis^{1,2†}, Aurélie Gouel-Chéron^{1,2,3†}, Friederike Jönsson^{1,2 *†} and Pierre Bruhns^{1,2 *†}

¹ Laboratoire Anticorps en Thérapie et Pathologie, Département d'Immunologie, Institut Pasteur, Paris, France

² U760, INSERM, Paris, France

³ Department of Anesthesia and Intensive Care, Hospital of Bichat-Claude Bernard, Public Assistance-Hospitals of Paris, Paris, France

Edited by:

Jan Terje Andersen, Oslo University Hosiptal, Norway

Reviewed by:

Beatrice Jahn-Schmid, Medical University of Vienna, Austria Sylvie Fournel, Strasbourg University, France

*Correspondence:

Friederike Jönsson and Pierre Bruhns, Laboratoire Anticorps en Thérapie et Pathologie, Département d'Immunologie, Institut Pasteur, 25 rue du Docteur Roux, Paris 75015, France e-mail: joensson@pasteur.fr; bruhns@pasteur.fr

[†]Caitlin Gillis and Aurélie Gouel-Chéron have contributed equally to this work.

⁺Friederike Jönsson and Pierre Bruhns are Co-senior authors. The biological activities of human IgG antibodies predominantly rely on a family of receptors for the Fc portion of IgG, Fc γ Rs: Fc γ RI, Fc γ RIIA, Fc γ RIIB, Fc γ RIIC, Fc γ RIIA, Fc γ RIIB, FcRL5, FcRn, and TRIM21. All Fc γ Rs bind IgG at the cell surface, except FcRn and TRIM21 that bind IgG once internalized. The affinity of Fc γ Rs for IgG is determined by polymorphisms of human Fc γ Rs and ranges from 2 × 10⁴ to 8 × 10⁷ M⁻¹. The biological functions of Fc γ Rs extend from cellular activation or inhibition, IgG-internalization/endocytosis/phagocytosis to IgG transport and recycling. This review focuses on human Fc γ Rs and intends to present an overview of the current understanding of how these receptors may contribute to various pathologies. It will define Fc γ Rs and their polymorphic variants, their affinity for human IgG subclasses, and review the associations found between Fc γ R polymorphisms and human pathologies. It will also describe the human Fc γ R-transgenic mice that have been used to study the role of these receptors in autoimmune, inflammatory, and allergic disease models.

Keywords: IgG receptors, transgenic mice, anaphylaxis, autoimmune diseases, genetic polymorphisms and disease association, human IgG receptors

INTRODUCTION ON HUMAN $Fc\gamma Rs:$ DEFINITION AND BASIC FUNCTIONS

Human myeloid cells, NK cells, and B cells are equipped with a variety of receptors that enable their interaction with monomeric or aggregated immunoglobulins, antigen–antibody immune complexes, and opsonized (antibody-coated) particles, cells, or surfaces. Most of these receptors bind the Fc portion of immunoglobulins (receptors for the Fc portion of immunoglobulins, FcR) and endow these cells with the capacity to interact with IgM, IgA, IgG, and/or IgE. This review will focus on IgG-binding human FcRs, FcγRs.

Humans express nine Fc γ Rs: the six classical Fc γ Rs, Fc γ RI, Fc γ RIIA, Fc γ RIIB, Fc γ RIIC, Fc γ RIIIA, and Fc γ RIIB; as well as FcRn, FcRL5 (1, 2), and TRIM21 (3) (**Figure 1**). These Fc γ Rs all bind IgG on the surface of the cells expressing them, except FcRn (4, 5) and TRIM21 (6, 7) that bind IgG once internalized. Notably, all IgG receptors bind at least two human IgG subclasses, albeit with varying binding affinity: the association constants (K_A) of IgG–Fc γ R interactions range from 8 × 10⁷ down to 2 × 10⁴ M⁻¹ (8) (**Figure 1**). Historically, Fc γ Rs were categorized as either *low-affinity* receptors that can only bind IgG when present in an immune complex, aggregated, or opsonized; or *high-affinity* receptors that can also bind free or monomeric IgG. This terminology has become rather obsolete considering reports of high- and low-affinity interactions for a single receptor toward

different Ig subclasses. Furthermore, although the prevailing belief was that occupancy of high-affinity receptors with pre-bound monomeric IgG prevents their participation in immediate IgGdependent reactions; this has recently been refuted *in vivo* (9). Adding to this complexity, human $Fc\gamma R$ polymorphisms that modulate affinity for some human IgG subclasses have been described (8) (refer to part 2; **Figure 1**).

Human FcyR expression on different cell types has been fairly comprehensively described, mostly by the use of FcyR-specific monoclonal antibodies (mAb) but also from data using mRNA profiling (Figure 2). Generally, the following observations can be made: hFcyRI (CD64) is restricted to monocytes/macrophages and dendritic cells and is inducibly expressed on neutrophils (10) and mast cells (11); hFcyRIIA (CD32A) is expressed on all myeloid cells but not on lymphocytes; hFcyRIIB (CD32B) is expressed at high levels only on B cells (12) and basophils (13). It is also expressed on tissue macrophages and dendritic cells (12), but only at low levels on 20% of circulating monocytes and 4% of circulating neutrophils (12, 14), and is not expressed on primary skin mast cells (15); hFcyRIIC (CD32C; refer to Section "Human FcγR Polymorphisms" for its "stop13" polymorphism) is expressed on NK cells (16), monocytes, and neutrophils (17); hFcyRIIIA (CD16A) is expressed on NK cells and monocytes/macrophages; hFcyRIIIB (CD16B) is highly expressed on neutrophils and at low levels on some basophils (18). TRIM21 (aka Ro52) was described

| Name | FcγRI | FcγF | RIIA | Fcγl | RIIB | Fcγl | RIIC | Fcγl | RIIIA | FcγRIIIB | FcRn | TRIM21 | FcRL5 |
|------------|-------------------|-------------------|-------------------|-------------------|-----------------------|-------------------|--------------------|------------------------------------|-------------------|-----------------------------------|--------------------------------|---|--|
| CD | CD64 | CD3 | 32A | CD | 32B | CD | 32C | CD | 16A | CD16B | - | - | CD307 |
| Gene | FCGR1A | FCG | R2A | FCG | R2B | FCG | R2C | FCG | GR3A | FCGR3B | FCGRT | TRIM21 | FCRL5 |
| | | 0 | | | | 0 |) | 0 | | GPI | β ₂ m | | 1-9 Ig-like domains |
| Alleles | Υ Υ2 | H ₁₃₁ | R ₁₃₁ | I ₂₃₂ | ■ T ₂₃₂ | Q ₁₃ | stop ₁₃ | γ ₂ V ₁₅₈ | F ₁₅₈ | NA1, | 4 | | <u>н</u> |
| 1-01 | 6x10 ⁷ | 5x10 ⁶ | 3x10 ⁶ | 1x10 ⁵ | ND | 1x10 ⁵ | | 2x10 ⁵ | 1x10 ⁵ | NA2, SH 2x10 ⁵ | 8x10 ⁷ | 5x10 ⁶ | 1x10 ⁶ |
| lgG1 | 6X10 | | | | | | - | | | 2X10° | | | |
| lgG2 | - | 4x10 ⁵ | 1x10⁵ | 2x10 ⁴ | ND | 2x10 ⁴ | - | 7x10 ⁴ | 3x10 ⁴ | - | 5x10 ⁷ | 5x10 ⁶ | variable |
| lgG3 | 6x10 ⁷ | 9x10 ⁵ | 9x10⁵ | 2x10 ⁵ | ND | 2x10 ⁵ | - | 1x10 ⁷ | 8x10 ⁶ | 1x10 ⁶ | 3x10 ⁷ | 2x10 ⁶ | 1x10 ⁵ |
| lgG4 | 3x10 ⁷ | 2x10 ⁵ | 2x10 ⁵ | 2x10 ⁵ | ND | 2x10 ⁵ | - | 2x10 ⁵ | 2x10 ⁵ | - | 2x10 ⁷ | 5x10 ⁶ | 1x10 ⁶ |
| Major role | Activation | Activa | ation | Inhib | ition | Activ | ration | Activ | vation | Decoy; Activation [≠] | lgG recycling; transport | Activation; proteasome addressing | Activation Proliferation Differentiation |

FIGURE 1 | Human IgG receptor family. Alleles are identified by the amino acid variant in the protein (e.g., H₁₃₁), or by the name of the allelic variants (NA1, NA2, or SH). Binding affinities for the various immunoglobulin subclasses are given as M⁻¹. High-affinity interactions are indicated in bold. –, no binding; ND, not determined;


[±]No allelic variants have yet been described that affect binding affinity #Associates with integrins. ITAM, immunoreceptor tyrosine-based activation motif; γ₂, dimer of FcRγ subunits; ITIM, immunoreceptor tyrosine-based inhibitory motif; GPI, glycosyl-phosphatidylinositol; β₂m, β₂-microglobulin.

to be widely expressed among lymphoid and myeloid populations, but also on endothelial cells (19). FcRL5 has been reported to be restricted to B cells (2).

These expression patterns highlight that hFcγRIIA is the only activating IgG receptor constitutively expressed by mast cells, basophils, neutrophils, and eosinophils, and that FCRL5 is the only activating IgG receptor constitutively expressed by B cells. Importantly, signal transduction events induced by human activating IgG receptors may be negatively regulated by hFcγRIIB only in B cells, dendritic cells, and basophils, and rare fractions of monocytes and neutrophils. Indeed, mast cells, NK cells, and most neutrophils and monocytes do not express this inhibitory receptor. hFcRn has been reported in dendritic cells, monocytes/macrophages (21), neutrophils (22), and endothelial cells (23), but expression on platelets and mast cells has not been examined so far.

These patterns correspond to the expression of Fc γ Rs in healthy individuals. These may be modified during pathological conditions or following therapeutic treatments. Certain cytokines for example have been reported to up-regulate or down-regulate some hFc γ Rs; e.g., B cells express higher levels of hFc γ RIIB following IFN- γ but lower levels following IL-4 stimulation, whereas opposite effects have been reported for monocytes [reviewed in Ref. (24)]. On the latter cells, expression of hFc γ RIIA is increased following IFN- γ and decreased following IL-4 stimulation (25). IL-3 stimulation, however, induces higher expression of both receptors (activating hFc γ RIIA and inhibitory hFc γ RIIB) on basophils (13). Mucosal mast cells express hFc γ RI upon IFN- γ stimulation (11). Surprisingly, IL-3 stimulation of primary monocytes did not modify hFc γ RI expression, but increased its ability to bind IgG-immune complexes and to induce intracellular activation signals (26).

Activating FcyRs signal through an immunoreceptor tyrosinebased activation motif (ITAM) that is either present in their intracytoplasmic domain or in associated signaling subunits, such as the FcR γ chain (Figure 1), the FcR β chain (exclusively in mast cells and basophils), or the CD3^{\zet} chain (exclusively in NK cells). These ITAM-containing structures allow FcyRs, once aggregated by multimeric ligands, to activate signaling cascades via SRC family kinases and spleen tyrosine kinase (SYK) leading to cell activation, cytokine/chemokine production, and cell migration (27-29). The inhibitory receptor FcyRIIB possesses instead an immunoreceptor tyrosine-based inhibition motif (ITIM) in its intracytoplasmic domain (30), which allows this receptor, once co-engaged with an activating FcyR, to recruit the inositol polyphosphate-5-phosphatase SHIP1 (31) that counteracts the signaling cascades initiated by activating FcyRs (24). FcRL5 possesses both an ITAM and two ITIMs; however, it has been reported to exert mainly negative regulatory functions (32). IgG receptors devoid of both ITAM and ITIM may induce cell activation by associating with other receptors at the cell membrane, for example the glycophosphatidylinositol-anchored FcyRIIIB (33, 34) associates with integrins (35); or by activating transcription pathways or proteasome-related mechanisms as does TRIM21 (7, 36).



rare subsets express the receptor; -, no expression; and NA, not analyzed; Mono/Macro, monocytes, and/or macrophages. § Refer

functional expression in non-conventional Fcgr2c-Stop persons (17).

Internalization of antibodies, and of the antigens they are bound to, represents the only shared function of IgG receptors expressed at the cell surface (that is, all except FcRn and TRIM21), whether ITAM-bearing, ITIM-bearing, or neither. FcyRs thereby enable antigen capture and internalization by all FcyR-expressing nucleated cells, as well as phagocytosis of opsonized bacteria, viruses, or cells by phagocytes. FcRn is the only receptor enabling transcytosis of IgG or IgG-IC by polarized cells (23). Enhanced uptake of antibody-bound antigen enables antigen-presenting cells to activate antigen-specific T cells considerably more efficiently than free antigen (37), signifying the pivotal role of FcyRs in the initial phase of humoral and cellular immune responses. Receptors that bind IgG only when it has already been internalized, FcRn (the topic of this review series) and the ubiquitously expressed intracellular receptor TRIM21, may possibly contribute to this phenomenon [reviewed in Ref. (20)].

HUMAN FcyR POLYMORPHISMS

DEFINITIONS

The multiplicity of human FcyRs (Figure 1) is increased by a series of genetic polymorphisms, for which we will describe herein only those leading to known functional modifications. These are summarized in Table 1.

Fcy RIIA

A polymorphism resulting in the presence of a histidine or an arginine residue at position 131 may also be referred to

as low-responder (H_{131}) or high-responder (R_{131}) (38). The FcyRIIA-H₁₃₁ allotype was originally reported to allow binding to IgG2 (53), subject to ethnic variation (54, 55), and was later described to also have increased binding for IgG3 (39). More recently, we have identified that only the binding to IgG1 and IgG2 are increased for H_{131} compared to R_{131} (8).

A novel splice variant of FCGR2A, FcyRIIA-exon 6*, containing an expressed cryptic exon 6* was identified in 2013 (41), and is associated with increased neutrophil sensitivity to IgG stimulation (56).

FcyRIIB

Single-nucleotide polymorphisms (SNPs) at positions 386 [IIB-386 (G/c)] and 120 [IIB-120 (T/a)], collectively constitute the 2B.4 promoter haplotype, which displays increased binding capacity for transcription factors GATA4 and Yin-Yang1, resulting in increased promoter activity and higher expression of FcyRIIB on monocytes, B lymphocytes, neutrophils, and myeloid DCs (24, 42).

A polymorphism encoding an isoleucine to threonine substitution at position 232 in the transmembrane domain of FcyRIIB (T₂₃₂) may disable receptor function via exclusion from lipid rafts (43, 57).

Fcy RIIC

In 20% of individuals FCGR2C encodes for a glutamine at position 13 (Q_{13} or ORF) and Fc γ RIIC is expressed; but in 80% of

| Receptor | Variant | Effect | Reference |
|----------|----------------------|---|-------------|
| FcγRIIA | H/R ₁₃₁ | H ₁₃₁ : ≯ binding of IgG2 and IgG1 | (8, 38–40) |
| | | ✓ Immune complex-opsonization | |
| | FcγRIIA-exon 6* | ≯ Activation following IgG stimulation | (41) |
| FcγRIIB | -386G/c | ≯ promoter activity: thus, ≯ FcγRIIB expression | (24, 42) |
| | —120T/a | | |
| | I/T ₂₃₂ | T_{232} : γ inhibitory function | (43) |
| FcγRIIC | Q/stop ₁₃ | Q ₁₃ : expression on NK cells, monocytes, neutrophils | (17) |
| | | ✓ IgG-induced cell activation | |
| | CNV | Correlation with protein expression levels | (44) |
| FcγRIIIA | V/F ₁₅₈ | V ₁₅₈ : ≯ binding to IgG1, IgG2, IgG3 | (8, 45, 46) |
| | | ✓ Cell activation | |
| | CNV | Correlation with protein expression levels; impaired NK cell cytotoxic function | (47) |
| FcγRIIIB | NA1/NA2/SH | NA1: 🖊 phagocytosis of IgG-immune complexes | (48–51) |
| | | SH: ≁ FcγRIIIB expression levels | |
| | CNV | Correlation with protein expression levels | (52) |

| Table 1 Summary of human | FcγR polymorphisms. |
|----------------------------|---------------------|
|----------------------------|---------------------|

individuals a SNP generates a stop codon (stop₁₃), in which case *FCGR2C* represents a pseudogene (16).

A subset of individuals carrying FCGR2C-ORF do not express Fc γ RIIC due to splice-site mutations and loss of exon 7. Inversely, this polymorphism leads to the expression of inhibitory hFc γ RIIB expression on NK cells that has been shown to negatively regulate IgG-induced NK cell activation (17).

Fcy RIIIA

A SNP determines the presence of a valine or phenylalanine at position 158 (45). The Fc γ RIIIA-V₁₅₈ variant demonstrates increased affinity for IgG1, IgG2, and IgG3, and increased IgG-induced cell activation and elimination of immune complexes (8, 46, 58).

FcyRIIIB

FcγRIIIB bears the neutrophil antigen (NA) in its membranedistal Ig-like domain, generating three variants termed NA1 (R₃₆ N₆₅ A₇₈ D₈₂ V₁₀₆), NA2 (S₃₆ S₆₅ A₇₈ N₈₂ I₁₀₆) (48, 59), and SH (S₃₆ S₆₅ D₇₈ N₈₂ I₁₀₆) (50) that do not demonstrate detectable differences in affinity for hIgG subclasses (8). The NA1 allotype was, however, reported to increase phagocytosis of IgG-opsonized particles (49). The SH allotype has been associated with higher FcγRIIIB expression levels (51).

Gene copy number variation (CNV)

Recognized as an important indicator for inter-individual differences, can alter the expression of activating IgG receptors. The balance between activating and inhibitory FcyRs can therefore be perturbed, altering cellular responses toward IgG-immune complexes. CNV of *FCGR2C*, *FCGR3A*, and *FCGR3B* (**Table 1**) have been shown to correlate with protein expression levels. Duplications of the gene encoding *FCGR3B* can lead to the expression of the three different FcyRIIIB variants (NA1, NA2, and SH) in a single individual (51). CNV in *FCGR3A* (deletion of one allele) correlated with a reduced expression of FcyRIIIA on NK cells and impaired cytotoxic function (47). Deletion of a large portion of the *FCGR* locus, including *FCGR2C* and *FCGR3B*, also resulted in abnormal expression of Fc γ RIIB on NK cells, presumably due to deletion of upstream regulatory elements. Expression of this inhibitory receptor enabled negative regulation of IgG-induced NK cell activation (17). To the extent of our knowledge, CNV of the *FCGR2A* and *FCGR2B* genes have not been reported (47).

ASSOCIATION WITH DISEASE SUSCEPTIBILITY AND/OR SUCCESS OF ANTIBODY-BASED THERAPIES

Several *FCGR* polymorphisms modify the affinity between Fc γ Rs and human IgG, and therefore the efficacy of immune complex clearance can be affected. Reduced immune complex clearance is indeed a risk factor for diseases like Systemic Lupus Erythematosus and Wegener's granulomatosis (60, 61). Other polymorphisms may favor detrimental inflammatory responses and thus predispose to autoimmunity. Diseases that have been associated with Fc γ R polymorphisms are presented in **Table 1**.

FcyR polymorphisms may also influence patients' response to treatment with intravenous immunoglobulin and therapeutic mAb. Almost all mAb used in therapy are based on human IgG1 antibodies, either chimeric mouse/human or fully human, allowing their interaction with all human FcyRs (8, 62). The first report to assess the predictive value of FcyR polymorphisms in responses to antibody therapies associated homozygous FCGR3A-V/V₁₅₈ individuals with better clinical responses to anti-CD20 therapy (Rituximab) in the treatment of non-Hodgkin lymphomas (63). Homozygous FCGR3A-V/V158 individuals have since been found to have improved biological responses to anti-CD20 therapy in immune thrombocytopenia (64) and rheumatoid arthritis (RA) (65); and anti-TNF- α therapy (Infliximab) to treat Crohn's disease (66, 67); compared to carriers of one or two FCGR3A-F₁₅₈ alleles. In arthritis patients, however, findings are controversial regarding the association of FCGR3A polymorphisms with clinical response to TNF- α inhibitors (infliximab, adalimumab, etanercept): although one study describes a better clinical response in FCGR3A-F/F₁₅₈ patients (68); another, larger study with a more homogenous patient cohort found no association (69). Homozygous FCGR3A-V/V158 individuals were more likely to experience complete remission from immune thrombocytopenia following medication, but conversely remission rates after splenectomy were higher in homozygous FCGR3A-F/F158 or heterozygous individuals (70). The FCGR2A-H131 variant associates with susceptibility to Kawasaki Disease (Table 1), whereas responsiveness to IVIG therapy in Kawasaki Disease patients is strongly associated with the FCGR3B genotype: the NA1 variant significantly decreases the odds of an appropriate clinical outcome (71). Similarly, CNV of both FCGR3B and FCGR2C were associated with Kawasaki Disease susceptibility and influenced IVIG treatment response (72). Furthermore, the FCGR2B minor alleles (IIB-386c and IIB-120a) conferring increased promoter activity were positively correlated to IVIG therapeutic response, although with limited statistical power over a small sample size (73). Each of these genetic associations is also constrained by unequal polymorphic variation between the different ethnic groups studied.

Altogether, particular Fc γ R polymorphisms have been described to be associated with the induction or severity of antibody-related disease, or patient responsiveness to antibody-based therapies. Nonetheless one should keep in mind that most Fc γ R-encoding genes are located within the 1q23 locus (*FCGR2A*, *FCGR3A*, *FCGR2B*, *FCGR2C*, *FCGR3B*) and may display a high degree of linkage disequilibrium, as reported for *FCGR2A* and *FCGR3A* (74) and for *FCGR2C* and *FCGR3B* (44). Association studies of Fc γ R-encoding genes should therefore include analyses of all Fc γ R-encoding genes from the 1q23 locus, and not focus on one particular gene.

IN VIVO ROLES OF HUMAN FcyRs: LESSONS FROM MOUSE MODELS¹

TRANSGENIC MOUSE MODELS EXPRESSING hFcyR(s)

Transgenic mouse studies have greatly enhanced our understanding of the *in vivo* function of hFc γ Rs. In particular, these studies have highlighted the respective contributions of hFc γ Rs to antibody-mediated inflammatory and allergic diseases (refer to Section "Understanding the Role of hFc γ Rs *In vivo* Using Transgenic Mouse Models: Illustrated in Autoimmune, Inflammatory, and Allergic Diseases"). Over the last two decades, various transgenic mouse strains have been generated that carry single or multiple hFc γ R-encoding genes (**Table 2**). Transgenic strains were initially generated on a wild-type mouse background; however, later studies have examined transgene expression in mice deficient for multiple endogenous mFc γ Rs, to specifically study the function of the transgenic human receptor.

The common approach to reproduce hFcyR expression patterns in mice is to use the genuine human promoter to drive transgene expression (**Table 2**). Whereas this strategy was successful for hFcyRIIA^{tg} and hFcyRIIIB^{tg} mice, both hFcyRI^{tg} mice and hFcyRIIB^{tg} mice exhibit somewhat abnormal expression [discussed in Ref. (62)]. hFcyRI^{tg} mice, for example, constitutively express substantial amounts of this receptor on neutrophils (37), while in humans hFcγRI is only inducibly expressed on neutrophils in contexts of inflammation, infection and during particular therapies [reviewed in Ref. (62)]. An alternative strategy consists of using a cell-specific promoter to drive hFcγR expression. hFcγRIIA^{tg}, hFcγRIIIB^{tg}, or double-transgenic mice were generated using the human MRP8 promoter to express these receptors on neutrophils and, abnormally for hFcγRIIB, on a proportion of monocytes (34). Finally, efforts made to cross the five single hFcγR-transgenic mouse strains with mFcγR^{null} mice – lacking mFcγRI, IIB, III, and IV – yielded a mouse model expressing most human IgG receptors – hFcγRI, IIA, IIB, IIIA, and IIIB – that preserves most human expression patterns (119) (**Table 2**).

UNDERSTANDING THE ROLE OF hFc γRs in vivo using transgenic mouse models: illustrated in autoimmune, inflammatory, and allergic diseases

FcR-mediated uptake of immune complexes and subsequent antigen presentation is a critical aspect of the immune response to foreign pathogens. Targeting of antigen to hFcyRI in hFcyRI^{tg} mice induced a strong antibody response, suggesting that hFcyRI on myeloid cells is capable of mediating antigen uptake and presentation in vivo (37, 120, 121). Various studies have demonstrated the capacity for hFcyRI and hFcyRIIIA to mediate cytotoxicity in the form of anti-tumor activity when engaged by bi-specific antibodies or antibodies with enhanced FcR binding, highlighting the effectiveness of such engineered antibody therapeutics in vivo (122-125). The role of FcyR in mediating anti-tumor therapies has recently been well-reviewed elsewhere (126, 127) and will not be discussed further in this review. hFcyR-transgenic mice have been useful both in understanding the in vivo function of these receptors and dissecting pathological mechanisms of disease; for illustration this section will describe results obtained in models of autoimmune thrombocytopenia, anaphylaxis, inflammation, and RA. Clearly, the biological responses to immobilized IgG are a function of their location, structure, and deposition, determining the subsequent recruitment and FcyR-mediated activation of immune cells: hFcyR-transgenic mice can assist us also in understanding the cell-specific role of FcyR in recruitment and immune complex clearance.

Autoimmune thrombocytopenia

Mice deficient for the FcR γ -subunit that is necessary for the expression of all mouse activating Fc γ Rs are resistant to antibodymediated platelet destruction, demonstrating the importance of activating Fc γ Rs in this model of autoimmune thrombocytopenia (128). Using transgenic mice, both hFc γ RI and hFc γ RIIA were found to be independently sufficient for platelet clearance (9, 129). In hFc γ RI^{tg} mice, thrombocytopenia was mediated by monocyte/macrophages outside of the spleen (9), whereas in hFc γ RIIA^{tg} mice, splenectomy was found to provoke a more severe phenotype of thrombosis and systemic shock when thrombocytopenia was induced by activating anti-platelet antibodies (130). Importantly, hFc γ RIIA^{tg} mice. It is likely, therefore, that the presence of this Fc γ R on the platelets themselves contributes to antibody-induced intravascular platelet activation that is most efficiently resolved

¹Note: for the sake of clarity, this section will use the terminology "hFcyR" for human IgG receptors, and "mFcyR" for mouse IgG receptors.

| Gene | SNP | Disease | Reference |
|--------|-------------------------------|---|--------------------------------------|
| FCGR2A | H ₁₃₁ | GBS, Kawasaki disease, idiopathic pulmonary fibrosis, and, for homozygous genotypes, MG, and children chronic ITP | (75–79) |
| | R ₁₃₁ | Bronchial asthma and allergic rhinitis, Still disease, Behçet's disease, refractory ITP, WG, MS, SLE, lupus nephritis, antiphospholipid syndrome, giant cell arteritis, rheumatic fever, ITP, and IgA nephropathy | (55, 60, 80–94) |
| | FcγRIIa-exon 6* | Anaphylaxis in patients with hypogammaglobulinemia, common variable immunodeficiency | (41) |
| FCGR2B | T ₂₃₂ 386C/120A | SLE, anti-GBM disease SLE, chronic inflammatory demyelinating polyneuropathy | (57, 95–99). (42, 100, 101) |
| FCGR2C | CNV | ITP, Kawasaki disease | (44, 72) |
| FCGR3A | F ₁₅₈ | SLE, Crohn's disease, Behçet's disease, severe GBS, bullous pemphigoid, WG relapses, RA, and for homozygotes, chronic ITP, and nephritis | (45, 60, 67, 70, 77, 93, 102–105) |
| | V ₁₅₈ | For homozygotes: RA susceptibility and severity, idiopathic inflammatory myopathies, and IgA nephropathy | (90, 106–108) |
| | CNV | Anti-GBM disease, RA | (109, 110) |
| FCGR3B | NA1 | For homozygotes: anti-neutrophil cytoplasmic antigen systemic vasculitis, chronic ITP in children, and severe course of MG | (75, 77, 111, 112) |
| | NA2 | SLE, severe GBS, Behçet's disease, IgA nephropathy, and MS | (85, 93, 105, 111, 113) |
| | SH | Alloimmune neonatal neutropenia, transfusion reactions | (50) |
| | CNV | Glomerulonephritis, SLE, systemic autoimmunity, RA, idiopathic pulmonary fibrosis, systemic sclerosis, and Kawasaki disease | (52, 72, 114–118) |

GBM, glomerular basement membrane; GBS, Guillain–Barré syndrome; ITP, idiotypic thrombocytopenic purpura; MG, myasthenia gravis; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosis; SNP, single nuclear polymorphism; WG, Wegener's granulomatosis.

by phagocytes in the spleen. These findings have implications for understanding human immune-mediated thrombocytopenic disorders, such as heparin-induced thrombocytopenia/thrombosis (HIT/T), a serious complication arising from the clinical use of heparin. Using hFcyRIIA^{tg} mice it was identified that antibodies against heparin-platelet factor 4 complexes are responsible for hFcyRIIA-mediated platelet activation, thrombocytopenia, and thrombi formation in the lung vasculature (131, 132). Similarly, thromboembolic complications from the use of monoclonal antibody therapies may be a result of hFcyRIIA-dependent platelet activation due to circulating immune complexes (133, 134). Another important outcome of these mouse studies is that the density of hFcyRIIA expression in the transgenic animal affects the severity of antibody-induced disease (130), which has critical ramifications for understanding differences in immune reactions between individuals. Finally, a therapeutic intervention targeting the hFcyRIIA-signaling pathway proved successful for the prevention of thrombocytopenia in hFcyRIIA^{tg} mice (135).

Anaphylactic reactions

Individuals who have developed antibodies against a given allergen can, upon re-exposure, develop a severe systemic allergic reaction (anaphylaxis). Allergen re-exposure induces the rapid formation of immune complexes that leads to cellular activation and release of vasoactive mediators, which drives the phenotype of systemic shock, including symptoms of hypotension and respiratory distress. Although anaphylaxis is classically attributed to an IgE-mediated mast cell-dependent paradigm of allergic reactivity, the same systemic symptoms can be reproduced experimentally in mice by the transfer of specific IgG antibodies and allergen, of preformed immune complexes (passive systemic anaphylaxis, PSA), or by repeated immunization with an antigen prior to challenge (active systemic anaphylaxis, ASA). hFcyRI and hFcyRIIA expressed in transgenic mice were each individually sufficient to mediate PSA, the symptoms of which may be alleviated by pretreatment with blocking antibodies (9, 136). PSA mediated by hFcyRIIA was found to be independent of mast cells and basophils, but rather dependent on neutrophils and monocytes/macrophages (136). Furthermore, hFcyRI and hFcyRIIA were identified as each individually sufficient to mediate ASA in transgenic mice, resulting in both hypothermia and death (9, 136). hFcyRI-dependent ASA required neutrophils and the release of platelet activating factor (9). These data demonstrate that hFcyR expressed on neutrophils and monocytes can mediate fatal anaphylactic reactions *in vivo*. Furthermore, in hFcyRI^{tg}IIA^{tg}IIB^{tg}IIIA^{tg}IIIB^{tg} mice (on the mFcyR^{null} background), administration of aggregated IgG was sufficient to trigger anaphylaxis (119). In addition, directly targeting either hFcyRI or hFcyRIIA by injection of agonistic mAb could induce anaphylaxis in transgenic mice (9, 136). Altogether, these data support the notion that anaphylaxis may also occur in humans in an hFcyR-dependent manner when allergen-specific IgGs are produced by an individual.

Immune complex induced inflammation

The formation of immune complexes is a hallmark of many human diseases, and their accumulation is an important trigger of inflammation-induced tissue damage. Pathogenic antibodies may bind directly to host cells, or immune complexes may deposit within tissues and trigger activation of local or circulating hFcγRexpressing cells. Using hFcγRIIA^{tg} mice, it was demonstrated that hFcγRIIA expressed on skin mast cells could trigger their activation following intradermal injection of immune complexes resulting in an inflammatory reaction in the skin (136). Inflammation of the airways due to local formation of immune complexes is characterized by granulocyte infiltration, elevated levels of myeloperoxidase, and subsequent damage to the lung epithelium, mimicking symptoms of asthmatic disease in humans. Whereas FcRγ-subunit^{-/-} mice are resistant to IC-induced airway inflammation, transgenic expression of either hFcγRI or hFcγRIIA was sufficient to restore this antibody-mediated pathology (9, 136).

Rheumatoid arthritis

Rheumatoid arthritis is an autoimmune disease in which the formation of immune complexes within the joints drives an inflammatory pathology. Autoantibodies directed against joint proteins such as collagen type II or glucose-6-phosphate isomerase (GPI) are found in RA patients, and the arthritis pathology may be modeled in mice by either active immunization with joint-associated components or by passive antibody transfer. hFcRn^{tg} mice provided direct evidence for the role of this receptor in serum persistence and transport of antibodies into tissues (23). Indeed, mFcRn^{-/-} mice are resistant to passive arthritis induction, and transgenic expression of hFcRn could restore arthritis susceptibility (137, 138); suggesting that greater IgG serum persistence may have implications for many autoimmune and inflammatory conditions (139). Surprisingly, transgenic expression of hFcyRIIA-R131 on a wild-type mouse background was associated with the spontaneous development of an RA-like joint pathology (140). Expression of hFcyRIIA indeed renders mice highly susceptible to various models of arthritis (140, 141), even if its expression is purposely restricted to neutrophils (142). Small inhibitors designed to bind antagonistically to hFcyRIIA were found to be protective (143), proposing a hFcyR-targeted therapy for RA. Besides hFcyRIIA^{tg} mice, other hFcyR-transgenic mice do not exhibit spontaneous joint inflammation. Nevertheless, hFcyRI^{tg} mice demonstrated that this receptor is sufficient to mediate arthritis induction in transgenic mice, dependent on the presence of both neutrophils and monocytes/macrophages (9). Therapeutic elimination of inflammatory macrophages by an hFcyRI-targeting immunotoxin inhibited the progression of experimental arthritis in hFcyRItg rats (144), and resolved cutaneous inflammation (145).

Cell-specific function of FcyR

Studies using hFc γ R^{tg} mice have enabled the description of specific *in vivo* functions not only for these IgG receptors, but also the cells that express them. Neutrophils are a particularly relevant example: the two main human neutrophil IgG receptors, hFc γ RIIA and hFc γ RIIIB, were found to individually and cooperatively promote IC-induced neutrophil recruitment and accumulation in the tissues. hFc γ RIIA alone, however, promoted associated injury and inflammation in multiple models of antibody-dependent autoimmunity. Importantly, neutrophil recruitment occurred despite the absence of Fc γ R expression on other cell types such as mast cells and macrophages, indicating a prominent role for hFc γ Rs on neutrophils in IC-induced recruitment (34). Furthermore, specialized functions may be attributed to these two neutrophil Fc γ R: hFc γ RIIIB seems to play an important role in homeostatic clearance of immune complexes deposited within the vasculature, whereas in a complex environment of immune complex deposition within the tissue and the vasculature, hFc γ RIIA was required for the formation of neutrophil extracellular traps (NETs) (146). Collectively, these data in hFc γ R^{tg} mice demonstrate the value of a transgenic approach to appreciate the role of human Fc γ R and the cells expressing them.

FINAL CONSIDERATIONS

Although, it is tempting to draw conclusions from genetic association studies performed in humans, it would be overreaching to delineate causal relationships between particular $Fc\gamma R$ variants and antibody-mediated human disease. Importantly, all the human $Fc\gamma R$ -transgenic mouse strains that have been reported express a single polymorphic variant of each $Fc\gamma R$ (**Table 3**). Thus, no comprehensive study can compare today the properties of a given polymorphism in mouse models of disease. Novel mouse models based on the exchange of the entire FCGR locus with that of humans may allow these comparison studies, or transgenic/knock-in mice expressing different polymorphic variants than the transgenic mice already reported, but remain to be generated. Still, when taking into account published data from both humans and animal models (referenced in **Tables 2** and **3**) several parallel observations have been described:

- Expression of hFcγRIIA (R₁₃₁) renders mice susceptible to arthritis and autoimmune pathologies including thrombocy-topenia (**Table 3**); and expression of hFcγRIIA-R₁₃₁ allotype is similarly associated with inflammatory diseases, thrombocy-topenia, and autoimmunity in humans (**Table 2**). The FcγRIIa-exon 6* polymorphic variant, which confers increased neutrophil sensitivity to IgG stimulation (**Table 1**) was also associated with anaphylactic responses in patients upon IVIG therapy (**Table 2**); consistent with data obtained in hFcγRIIA^{tg} mice indicating that neutrophils can contribute to IgG-dependant anaphylaxis mediated by FcγRIIA.
- The NA1 allotypic variant of FcγRIIIB confers increased phagocytosis of IgG-immune complexes, and is associated with thrombocytopenia in humans; whereas FcγRIIIB-NA2 and CNV are associated with inflammatory and autoimmune conditions characterized by immune complex deposition. These data are congruent with findings in NA2-hFcγRIIIB^{tg} mice (**Table 2**), demonstrating an important role for this receptor in mediating neutrophil recruitment as well as homeostatic clearance of immune complexes.

While genetic association studies identify important risk factors and inform on the involvement of $Fc\gamma R$ in human disease; $hFc\gamma R^{tg}$ mice allow us to more precisely dissect pathological mechanisms, and describe the role of human $Fc\gamma R$ and the cells expressing them in various clinically relevant pathologies. Together, these data in humans and transgenic models highlight the contribution of $hFc\gamma R$ to antibody-mediated diseases, and open avenues for understanding pathogenic mechanisms. Such data will continue

| Table 3 I | hFcyR-transgenic mouse models: description and main results obtained. |
|-------------|---|
|-------------|---|

| Promoter | Expression | Variant | Strain | <i>In vivo</i> findings | Reference |
|-----------|--------------------------------|-----------------------------------|-------------------------------------|---|-----------------------|
| CD64 (hFc | γRI) | | | | |
| FCGR1 | Monocytes, macrophages, | | FVB/N | Bi-specific mAb-dependent hFcγRI-triggered killing (<i>in vitro</i>) | (122) |
| | DCs, neutrophils | | FVB/N | Anti-hFc γ RI mAb immunization elicits higher Ab responses | (37) |
| | | | FVB/N | hFcyRI-mediated binding and phagocytosis of opsonized RBCs | (147) |
| | | | ? | Antigen targeting to hFcyRI increased vaccination potency | (120) |
| | | | FVB/N | Weak antigen targeting to hFcyRI enhances immunogenicity | (121) |
| | | | FVB/N | Immunotoxin targeting of hFcyRI reduces inflammation | (145) |
| | | | 5KO (B6 F6) | hFcyRI-dependent arthritis, thrombocytopenia, airway | (9) |
| | | | 0110 (2010) | inflammation, and anaphylaxis (PSA and ASA) | (0) |
| CD32A (hF | FcyRIIA) | | | | |
| CGR2A | Monocytes, macrophages, | R ₁₃₁ | FcR $\gamma^{-/-}$ (B6xSJL) | Immune thrombocytopenia can be induced via $hFc\gamma RIIA$ | (129) |
| | neutrophils, eosinophils, | | $FcR\gamma^{-/-}$ (B6) | hFcyRIIA-dependent thrombosis and shock | (130) |
| | basophils, mast cells, DCs, | | hPF4 ^{tg} (B6) | hFcyRIIA-dependent Heparin-induced thrombocytopenia | (131) |
| | megakaryocyte, platelets | | C57BL/6 | Increased active and passive collagen-induced arthritis | (140) |
| | | | FcR $\gamma^{-/-}$ (B6xSJL) | hFcyRIIA mediates experimental immune hemolytic anemia | (148) |
| | | | hPF4 ^{tg} lo/hi (B6) | PF4-hFcγRIIA-dependent Heparin-induced thrombocytopenia | (132) |
| | | | C57BL/6 \times SJL F ₁ | hFcyRIIA-dependent platelet activation by Bevacizumab IC | (133) |
| | | | C57BL/6 \times SJL F ₁ | Small chemical entities inhibit collagen-induced arthritis | (143) |
| | | | C57BL/6 \times SJL F ₁ | hFcyRIIA-dependent platelet activation by CD40L IC | (134) |
| | | | C57BL/6 \times SJL F ₁ | Increased sensitivity to autoimmune arthritis | (141) |
| | | | C57BL/6 | Inhibition of hFcyRIIA-signaling pathway to inhibit thrombosis | (135) |
| | | | | and thrombocytopenia | (/ |
| | | | FcRγ ^{-/-} ,5KO | hFcγRIIA induces anaphylaxis and airway inflammation | (136) |
| | | | C57BL/6J | $hFc\gamma RIIA$ cooperates with integrin signaling in platelets | (149) |
| MRP8 | Neutrophils, some monocytes | R ₁₃₁ | FcγR ^{-/-} | hFcγRIIA-dependent nephritis, Arthus reaction, neutrophil recruitment and tissue injury | (34) |
| | | | FcγR ^{-/-} | Neutrophil hFcyRIIA is sufficient for arthritis induction | (142) |
| | | | FcγR ^{-/-} | hFcγRIIA-dependent NETosis in Arthus reaction | (146) |
| CD32B (hF | FovRIIB) | | 10,11 | | (140) |
| CGR2B | B cells, splenic CD11c | I ₂₃₂ | C57BI/6 | Crosslinking hFcyRIIB and CD19 suppresses humoral immunity | (150) |
| | DCs, monocytes, | | | in systemic lupus erythematosus | |
| | neutrophils, eosinophils | | $FcR\gamma^{-/-}$ or | hFcyRIIB-enhanced immunostimulatory and anti-tumor activity | (151) |
| | | | FcγRIIB ^{-/-} | of chimeric mouse–human agonistic anti-CD40 Abs | |
| | | | CD40 ^{-/-} | Anti-tumor activity of agonistic anti-TNFR Abs requires | (152) |
| | | | | differential hFcyRIIB coengagement | |
| CD16A (hF | • • | | | | |
| CGR3A | NK cells, macrophages | F ₁₅₈ | B6xCBAFI | Promoter/expression analysis | (153) |
| , | NK cells and ? | ? | SCID | Glycoengineering of a humanized anti-EGFR Ab leads to enhanced ADCC through $hFc\gamma RIIIA$ | (125) |
| CD16B (hF | FcγRIIIB) | | | | |
| CGR3B | Neutrophils | ? | B6xCBAFI | Promoter/expression analysis | (153) |
| ARP8 | Neutrophils, some monocytes | NA2 | FcRγ ^{-/-} | hFcyRIIIB is sufficient for NTS nephritis, cutaneous RPA reaction and promotes neutrophil recruitment | (34) |
| | | | FcRγ ^{-/-} | hFcyRIIIB mediates neutrophil tethering to intravascular immune complexes and their uptake | (146) |
| CD32A (hF | FcyRIIA) + CD16B (hFcyRIIIB) | | | | |
| ARP8 | Neutrophils, some monocytes | IIA: R ₁₃₁ IIIB:NA2 | FcRγ ^{-/-} | hFcyRIIA and hFcyRIIIB cooperate to induce nephritis and cutaneous Arthus reaction | (34) |

(Continued)

Table 3 | Continued

| Promoter | Expression | Variant | Strain | <i>In vivo</i> findings | Reference |
|---|---|--|---|--|-----------|
| FcyR-HUM | ANIZED MICE (INTERCRO |)SS OF hFcyF | RI ^{tg} , IIA ^{tg} , IIB ^{tg} , IIIA ^t | ^g AND IIIB ^{tg} MICE) | |
| FCGR1 FCGR2A FCGR2B FCGR3A FCGR3B | Please refer to single transgenic mice | I IIA-R ₁₃₁ IIB-I ₂₃₂ IIIA-F ₁₅₈ IIIB-? | mFcγRI ^{-/-} mFcγRIIB ^{-/-} mFcγRIII ^{-/-} mFcγRIV ^{-/-} | Antibody-mediated FcγR-dependent cell depletion (B cells, T cells, platelets), and B16-F10 lung metastasis clearance FcγR-mediated IC-induced systemic anaphylaxis | (119) |
| hFcRn | | | | | |
| FCGRT | Intestine and ? | | mFcRn ^{-/-} | hFcRn expression restores serum half life of hIgG in mFcRn ^{-/-} mice | (154) |
| | | | mFcRn ^{-/-} ; mFcRn ^{-/-} FcyRIIB ^{-/-} | hlgG with engineered high FcRn binding affinity has enhanced half life <i>in vivo</i> ; inhibition of the binding of pathogenic Abs to hFcRn ameliorates arthritis | (137) |
| | | | mFcRn ^{-/-} mβ2m ^{-/-} hFcRn ^{tg} hβ2m ^{tg} | Blocking hFcRn using a peptide antagonist increases hIgG catabolism | (155) |
| | | | 6KO (B6 F6) | hFcRn restores arthritis susceptibility in 6KO mice | (138) |

?, information unavailable in the original publication.

to impact on therapeutic choices and potentially identify new interventional targets.

ACKNOWLEDGMENTS

Works of our laboratory discussed in this review were supported by the Institut Pasteur, the Institut National de la Santé et de la Recherche Médicale (INSERM), the Agence Nationale pour la Recherche (grant GENOPAT-09-GENO-014-01), the Société Française d'Allergologie (SFA), and the company Balsan. Caitlin Gillis is a scholar of the Pasteur Paris University International Doctoral Program (PPUIDP) and received a stipend from the Institut Carnot Pasteur Maladies Infectieuses. Friederike Jönsson is a *chargé de recherche* (Investigator) at the Centre National de la Recherche Scientifique (CNRS).

REFERENCES

- Wilson TJ, Fuchs A, Colonna M. Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG. J Immunol (2012) 188:4741–5. doi:10.4049/ jimmunol.1102651
- Franco A, Damdinsuren B, Ise T, Dement-Brown J, Li H, Nagata S, et al. Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors. J Immunol (2013) 190:5739–46. doi:10.4049/jimmunol.1202860
- Yang Y, Eversole T, Lee DJ, Sontheimer RD, Capra JD. Protein-protein interactions between native Ro52 and immunoglobulin G heavy chain. *Scand J Immunol* (1999) 49:620–8. doi:10.1046/j.1365-3083.1999.00547.x
- Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. *Nature* (1989) 337:184–7. doi:10.1038/337184a0
- Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. *J Immunol* (2004) 172:2021–9. doi:10.4049/jimmunol.172.4.2021
- James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. *Proc Natl Acad Sci U S A* (2007) 104:6200–5. doi:10.1073/pnas.0609174104
- Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motifcontaining 21 (TRIM21). *Proc Natl Acad Sci U S A* (2010) 107:19985–90. doi:10.1073/pnas.1014074107
- 8. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fc{gamma} receptors and their

polymorphic variants for human IgG subclasses. *Blood* (2009) **113**:3716–25. doi:10.1182/blood-2008-09-179754

- Mancardi DA, Albanesi M, Jonsson F, Iannascoli B, van Rooijen N, Kang X, et al. The high-affinity human IgG receptor FcgammaRI (CD64) promotes IgGmediated inflammation, anaphylaxis, and antitumor immunotherapy. *Blood* (2013) 121:1563–73. doi:10.1182/blood-2012-07-442541
- 10. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol (1991) 9:457–92. doi:10.1146/annurev.iy.09.040191.002325
- Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional highaffinity IgG receptor, Fc gamma RI, on human mast cells: up-regulation by IFN-gamma. *J Immunol* (2000) 164:4332–9. doi:10.4049/jimmunol.164.8. 4332
- Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, et al. Monoclonal antibodies capable of discriminating the human inhibitory Fcgammareceptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. *Immunology* (2007) 121:392–404. doi:10.1111/j.1365-2567.2007.02588.x
- Cassard L, Jonsson F, Arnaud S, Daeron M. Fcgamma receptors inhibit mouse and human basophil activation. J Immunol (2012) 189:2995–3006. doi:10.4049/jimmunol.1200968
- Magnusson SE, Engstrom M, Jacob U, Ulfgren AK, Kleinau S. High synovial expression of the inhibitory FcgammaRIIb in rheumatoid arthritis. *Arthritis Res Ther* (2007) 9:R51. doi:10.1186/ar2206
- Zhao W, Kepley CL, Morel PA, Okumoto LM, Fukuoka Y, Schwartz LB. Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells. *J Immunol* (2006) 177:694–701. doi:10.4049/jimmunol.177.1.694
- Metes D, Ernst LK, Chambers WH, Sulica A, Herberman RB, Morel PA. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene. *Blood* (1998) **91**: 2369–80.
- van der Heijden J, Breunis WB, Geissler J, De Boer M, van den Berg TK, Kuijpers TW. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. *J Immunol* (2012) 188:1318–24. doi:10.4049/jimmunol.1003945
- Meknache N, Jönsson F, Laurent J, Guinnepain MT, Daëron M. Human basophils express the glycosylphosphatidylinositol-anchored low-affinity IgG receptor Fc{gamma}RIIIB (CD16B). *J Immunol* (2009) 182:2542–50. doi:10. 4049/jimmunol.0801665
- Espinosa A, Dardalhon V, Brauner S, Ambrosi A, Higgs R, Quintana FJ, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med (2009) 206:1661–71. doi:10.1084/jem.20090585

- Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. *Nat Rev Immunol* (2014) 14:94–108. doi:10.1038/nri3582
- Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. *J Immunol* (2001) 166:3266–76. doi:10.4049/jimmunol.166.5.3266
- 22. Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, Rebers FE, et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. *Blood* (2006) **108**:3573–9. doi:10.1182/blood-2006-05-024539
- Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7:715–25. doi:10.1038/nri2155
- Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. *Nat Rev Immunol* (2010) 10:328–43. doi:10.1038/nri2762
- Pricop L, Redecha P, Teillaud JL, Frey J, Fridman WH, Sautes-Fridman C, et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol (2001) 166:531–7. doi:10.4049/jimmunol.166.1.531
- 26. van der Poel CE, Karssemeijer RA, Boross P, van der Linden JA, Blokland M, van de Winkel JG, et al. Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcgammaRI, in the presence of monomeric IgG. *Blood* (2010) **116**:5327–33. doi:10.1182/blood-2010-04-280214
- 27. Daëron M. Fc receptor biology. Annu Rev Immunol (1997) 15:203–34. doi:10. 1146/annurev.immunol.15.1.203
- Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 8:34–47. doi:10.1038/nri2206
- Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. *Immunol Rev* (2009) 232:59–71. doi:10.1111/j.1600-065X.2009.00832.x
- Amigorena S, Bonnerot C, Drake JR, Choquet D, Hunziker W, Guillet JG, et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. *Science* (1992) 256:1808–12. doi:10.1126/science.1535455
- Ono M, Bolland S, Tempst P, Ravetch JV. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. *Nature* (1996) 383:263–6. doi:10.1038/383263a0
- 32. Zhu Z, Li R, Li H, Zhou T, Davis RS. FCRL5 exerts binary and compartmentspecific influence on innate-like B-cell receptor signaling. *Proc Natl Acad Sci U* S A (2013) 110:E1282–90. doi:10.1073/pnas.1215156110
- 33. Kimberly RP, Ahlstrom JW, Click ME, Edberg JC. The glycosyl phosphatidylinositol-linked Fc gamma RIIIPMN mediates transmembrane signaling events distinct from Fc gamma RII. J Exp Med (1990) 171:1239–55. doi:10.1084/jem.171.4.1239
- 34. Tsuboi N, Asano K, Lauterbach M, Mayadas TN. Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibodymediated inflammatory diseases. *Immunity* (2008) 28:833–46. doi:10.1016/j. immuni.2008.04.013
- Todd RF III, Petty HR. Beta 2 (CD11/CD18) integrins can serve as signaling partners for other leukocyte receptors. J Lab Clin Med (1997) 129:492–8. doi:10.1016/S0022-2143(97)90003-2
- McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. *Nat Immunol* (2013) 14:327–36. doi:10.1038/ni.2548
- 37. Heijnen IA, van Vugt MJ, Fanger NA, Graziano RF, De Wit TP, Hofhuis FM, et al. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. *J Clin Invest* (1996) 97:331–8. doi:10.1172/JCI118420
- Warmerdam PA, van de Winkel JG, Gosselin EJ, Capel PJ. Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J Exp Med (1990) 172:19–25. doi:10.1084/jem.172.1.19
- 39. Parren PW, Warmerdam PA, Boeije LC, Arts J, Westerdaal NA, Vlug A, et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. *J Clin Invest* (1992) **90**:1537–46. doi:10.1172/JCI116022
- Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. *J Clin Invest* (1992) 89:1274–81. doi:10.1172/JCI115712

- 41. van der Heijden J, Geissler J, van Mirre E, van Deuren M, van der Meer JW, Salama A, et al. A novel splice variant of FcgammaRIIa: a risk factor for anaphylaxis in patients with hypogammaglobulinemia. *J Allergy Clin Immunol* (2013) **131**(1408–1416):e1405. doi:10.1016/j.jaci.2013.02.009
- 42. Su K, Wu J, Edberg JC, Li X, Ferguson P, Cooper GS, et al. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcγRIIb alters receptor expression and associates with autoimmunity. I. Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus. J Immunol (2004) 172:7186–91. doi:10.4049/jimmunol.172.11.7186
- 43. Li X, Wu J, Carter RH, Edberg JC, Su K, Cooper GS, et al. A novel polymorphism in the Fcγ receptor IIB (CD32B) transmembrane region alters receptor signaling. *Arthritis Rheum* (2003) 48:3242–52. doi:10.1002/art.11313
- 44. Breunis WB, van Mirre E, Bruin M, Geissler J, De Boer M, Peters M, et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. *Blood* (2008) 111:1029–38. doi:10.1182/blood-2007-03-079913
- 45. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. *J Clin Invest* (1997) 100:1059–70. doi:10.1172/JCI119616
- 46. Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem (2006) 281:5032–6. doi:10.1074/jbc.M510171200
- 47. Breunis WB, van Mirre E, Geissler J, Laddach N, Wolbink G, van der Schoot E, et al. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. *Hum Mutat* (2009) **30**:E640–50. doi:10.1002/humu.20997
- Ory PA, Clark MR, Kwoh EE, Clarkson SB, Goldstein IM. Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest (1989) 84:1688–91. doi:10.1172/JCI114350
- Salmon JE, Edberg JC, Kimberly RP. Fc gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities. J Clin Invest (1990) 85:1287–95. doi:10.1172/JCI114566
- Bux J, Stein EL, Bierling P, Fromont P, Clay M, Stroncek D, et al. Characterization of a new alloantigen (SH) on the human neutrophil Fc gamma receptor IIIb. *Blood* (1997) 89:1027–34.
- 51. Koene HR, Kleijer M, Roos D, De Haas M, Von Dem Borne AEGK. FcγRIIIB gene duplication: evidence for presence and expression of three distinct FcγRIIIB genes in NA(1+,2+)SH(+) individuals. *Blood* (1998) **91**: 673–9.
- 52. Willcocks LC, Lyons PA, Clatworthy MR, Robinson JI, Yang W, Newland SA, et al. Copy number of FCGR3B, which is associated with systemic lupus ery-thematosus, correlates with protein expression and immune complex uptake. *J Exp Med* (2008) 205:1573–82. doi:10.1084/jem.20072413
- 53. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. *J Immunol* (1991) 147:1338–43.
- Osborne JM, Chacko GW, Brandt JT, Anderson CL. Ethnic variation in frequency of an allelic polymorphism of human Fc gamma RIIA determined with allele specific oligonucleotide probes. *J Immunol Methods* (1994) 173:207–17. doi:10.1016/0022-1759(94)90299-2
- 55. Lehrnbecher T, Foster CB, Zhu S, Leitman SF, Goldin LR, Huppi K, et al. Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations. *Blood* (1999) **94**:4220–32.
- 56. van der Heijden J, Nagelkerke S, Zhao X, Geissler J, Rispens T, van den Berg TK, et al. Haplotypes of FcgammaRIIa and FcgammaRIIIb polymorphic variants influence IgG-mediated responses in neutrophils. *J Immunol* (2014) **192**(6):2715–21. doi:10.4049/jimmunol.1203570
- 57. Floto RA, Clatworthy MR, Heilbronn KR, Rosner DR, Macary PA, Rankin A, et al. Loss of function of a lupus-associated Fc[gamma]RIIb polymorphism through exclusion from lipid rafts. *Nat Med* (2005) **11**:1056–8. doi:10.1038/ nm1288
- Takai T. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol (2005) 25:1–18. doi:10.1007/s10875-005-0353-8
- Huizinga T, Kleijer M, Tetteroo P, Roos D, Von Dem Borne A. Biallelic neutrophil Na-antigen system is associated with a polymorphism on the phosphoinositol-linked Fc gamma receptor III (CD16). *Blood* (1990) 75:213–7.

- 60. Dijstelbloem HM, Scheepers RHM, Oost WW, Stegeman CA, van der Pol WL, Sluiter WJ, et al. Fcγ receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. *Arthritis Rheum* (1999) 42:1823–7. doi:10.1002/ 1529-0131(199909)42:9<1823::AID-ANR5>3.0.CO;2-X
- 61. Dijstelbloem HM, Bijl M, Fijnheer R, Scheepers RHM, Oost WW, Jansen MD, et al. Fcγ receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. *Arthritis Rheum* (2000) 43:2793–800. doi:10.1002/1529-0131(200012)43:12<2793: :AID-ANR20>3.0.CO;2-6
- Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. *Blood* (2012) 119:5640–9. doi:10.1182/blood-2012-01-380121
- Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. *Blood* (2002) 99:754–8. doi:10.1182/blood.V99.3.754
- 64. Cooper N, Stasi R, Cunningham-Rundles S, Cesarman E, McFarland JG, Bussel JB. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. *Br J Haematol* (2012) **158**:539–47. doi:10.1111/j.1365-2141.2012.09184.x
- 65. Ruyssen-Witrand A, Rouanet S, Combe B, Dougados M, Le Loët X, Sibilia J, et al. Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. *Ann Rheum Dis* (2012) **71**:875–7. doi:10.1136/annrheumdis-2011-200337
- 66. Louis E, El Ghoul Z, Vermeire S, Dall'ozzo S, Rutgeerts P, Paintaud G, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. *Aliment Pharmacol Ther* (2004) 19:511–9. doi:10.1111/j.1365-2036.2004.01871.x
- 67. Moroi R, Endo K, Kinouchi Y, Shiga H, Kakuta Y, Kuroha M, et al. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. *Immunogenetics* (2013) **65**:265–71. doi:10.1007/s00251-013-0679-8
- 68. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α-blocking agents. *Arthritis Rheum* (2005) **52**:2693–6. doi:10.1002/art.21266
- 69. Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Söderkvist P, et al. Fcγ receptor type IIIA genotype and response to tumor necrosis factor α-blocking agents in patients with rheumatoid arthritis. *Arthritis Rheum* (2007) 56:448–52. doi:10.1002/art.22390
- Fujimoto T-T, Inoue M, Shimomura T, Fujimura K. Involvement of Fcγ receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura. *Br J Haematol* (2001) **115**:125–30. doi:10.1046/j.1365-2141.2001. 03109.x
- 71. Shrestha S, Wiener H, Shendre A, Kaslow RA, Wu J, Olson A, et al. Role of activating FcγR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response. *Circ Cardiovasc Genet* (2012) 5:309–16. doi:10.1161/CIRCGENETICS.111.962464
- Makowsky R, Wiener HW, Ptacek TS, Silva M, Shendre A, Edberg JC, et al. FcgammaR gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response. *Pharmacogenet Genomics* (2013) 23:455–62. doi:10.1097/FPC.0b013e328363686e
- Shrestha S, Wiener HW, Olson AK, Edberg JC, Bowles NE, Patel H, et al. Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease. *J Allergy Clin Immunol* (2011) 128:677–80. doi:10.1016/j.jaci.2011.04.027
- Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M. Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. *J Clin Oncol* (2008) 26:5489–91. doi:10.1200/JCO.2008.19.4118
- Raknes G, Skeie GO, Gilhus NE, Aadland S, Vedeler C. FcγRIIA and FcγRIIIB polymorphisms in myasthenia gravis. J Neuroimmunol (1998) 81:173–6. doi:10.1016/S0165-5728(97)00174-4
- 76. van der Pol W-L, van den Berg LH, Scheepers RHM, van der Bom JG, van Doorn PA, van Koningsveld R, et al. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome. *Neurology* (2000) 54:1661–5. doi:10.1212/WNL54.8.1661

- Foster CB, Zhu S, Erichsen HC, Lehrnbecher T, Hart ES, Choi E, et al. Polymorphisms in inflammatory cytokines and Fcγ receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. *Br J Haematol* (2001) 113:596–9. doi:10.1046/j.1365-2141.2001.02807.x
- Bournazos S, Grinfeld J, Alexander K, Murchison J, Wallace W, McFarlane P, et al. Association of FcgammaRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression. *BMC Pulm Med* (2010) 10:51. doi:10.1186/1471-2466-10-51
- Khor CC, Davila S, Breunis WB, Lee Y-C, Shimizu C, Wright VJ, et al. Genomewide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. *Nat Genet* (2011) 43:1241–6. doi:10.1038/ng.981
- Sanders LAM, van de Winkel JGJ, Rijkers GT, Voorhorst-Ogink MM, De Haas M, Capel PJA, et al. Fcã receptor Iia (Cd32) heterogeneity in patients with recurrent bacterial respiratory tract infections. *J Infect Dis* (1994) **170**:854–61. doi:10.1093/infdis/170.4.854
- Duits AJ, Bootsma H, Derksen RH, Spronk PE, Kater L, Kallenberg CG, et al. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. *Arthritis Rheum* (1995) 38:1832–6. doi:10.1002/art.1780381217
- Edberg JC, Wainstein E, Wu J, Csernok E, Sneller MC, Hoffman GS, et al. Analysis of FcgammaRII gene polymorphisms in Wegener's granulomatosis. *Exp Clin Immunogenet* (1997) 14:183–95.
- Haseley LA, Wisnieski JJ, Denburg MR, Michael-Grossman AR, Ginzler EM, Gourley MF, et al. Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to Fc gamma RIIA alleles. *Kidney Int* (1997) 52:1375–80. doi:10.1038/ki.1997.464
- Williams Y, Lynch S, McCann S, Smith O, Feighery C, Whelan A. Correlation of platelet FcγRIIA polymorphism in refractory idiopathic (immune) thrombocytopenic purpura. *Br J Haematol* (1998) **101**:779–82. doi:10.1046/j.1365-2141.1998.00802.x
- Myhr K-M, Raknes G, Nyland H, Vedeler C. Immunoglobulin G Fc-receptor (FcγR) IIA and IIIB polymorphisms related to disability in MS. *Neurology* (1999) 52:1771. doi:10.1212/WNL.52.9.1771
- 86. Norsworthy P, Theodoridis E, Botto M, Athanassiou P, Beynon H, Gordon C, et al. Overrepresentation of the Fcγ receptor type IIA R131/R131 genotype in Caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis. *Arthritis Rheum* (1999) 42:1828–32. doi:10.1002/1529-0131(19990)42:9<1828::AID-ANR6>3.0.CO;2-F
- Yun HR, Koh HK, Kim SS, Chung WT, Kim DW, Hong KP, et al. FcgammaRIIa/IIIa polymorphism and its association with clinical manifestations in Korean lupus patients. *Lupus* (2001) 10:466–72. doi:10.1191/ 096120301678416015
- Karassa FB, Trikalinos TA, Ioannidis JPA. Role of the Fcγ receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. *Arthritis Rheum* (2002) 46:1563–71. doi:10.1002/ art.10306
- Karassa FB, Bijl M, Davies KA, Kallenberg CGM, Khamashta MA, Manger K, et al. Role of the Fcγ receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. *Arthritis Rheum* (2003) 48:1930–8. doi:10.1002/art.11059
- Tanaka Y, Suzuki Y, Tsuge T, Kanamaru Y, Horikoshi S, Monteiro RC, et al. FcgammaRIIa-131R allele and FcgammaRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy. *Nephrol Dial Transplant* (2005) 20:2439–45. doi:10.1093/ndt/gfi043
- Morgan AW, Robinson JI, Barrett JH, Martin J, Walker A, Babbage SJ, et al. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. *Arthritis Res Ther* (2006) 8:R109. doi:10.1186/ar1996
- 92. Gulen F, Tanac R, Altinoz S, Berdeli A, Zeyrek D, Koksoy H, et al. The FcγRIIa polymorphism in Turkish children with asthma bronchial and allergic rhinitis. *Clin Biochem* (2007) **40**:392–6. doi:10.1016/j.clinbiochem.2006.11.014
- 93. Aksu K, Kitapcioglu G, Keser G, Berdeli A, Karabulut G, Kobak S, et al. FcgammaRIIa, IIIa and IIIb gene polymorphisms in Behcet's disease: do they have any clinical implications? *Clin Exp Rheumatol* (2008) **26**:S77–83.
- 94. Woo J-H, Sung Y-K, Lee J-S, Chung WT, Choe J-Y, Song GG, et al. Association of Fcγ receptor polymorphisms with adult onset still's disease in Korea. *J Rheumatol* (2009) 36:347–50. doi:10.3899/jrheum.071254
- 95. Kyogoku C, Dijstelbloem HM, Tsuchiya N, Hatta Y, Kato H, Yamaguchi A, et al. Fcγ receptor gene polymorphisms in Japanese patients with systemic

lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum (2002) **46**:1242–54. doi:10.1002/art.10257

- 96. Siriboonrit U, Tsuchiya N, Sirikong M, Kyogoku C, Bejrachandra S, Suthipinittharm P, et al. Association of Fcγ receptor IIb and IIIb polymorphisms with susceptibility to systemic lupus erythematosus in Thais. *Tissue Antigens* (2003) 61:374–83. doi:10.1034/j.1399-0039.2003.00047.x
- 97. Kono H, Kyogoku C, Suzuki T, Tsuchiya N, Honda H, Yamamoto K, et al. FcγRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. *Hum Mol Genet* (2005) 14:2881–92. doi:10.1093/hmg/ddi320
- Willcocks LC, Carr EJ, Niederer HA, Rayner TF, Williams TN, Yang W, et al. A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus. *Proc Natl Acad Sci* U S A (2010) 107:7881–5. doi:10.1073/pnas.0915133107
- 99. Zhou X-J, Lv J-C, Yu L, Cui Z, Zhao J, Yang R, et al. FCGR2B gene polymorphism rather than FCGR2A, FCGR3A and FCGR3B is associated with anti-GBM disease in Chinese. *Nephrol Dial Transplant* (2010) 25:97–101. doi:10.1093/ndt/gfp374
- 100. Blank M, Stefanescu R, Masuda E, Marti F, King P, Redecha P, et al. Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. *Hum Genet* (2005) 117:220–7. doi:10.1007/s00439-005-1302-3
- 101. Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, et al. Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. *Proc Natl Acad Sci U S A* (2009) 106:4788–92. doi:10.1073/pnas.0807319106
- 102. Koene HR, Kleijer M, Swaak AJ, Sullivan KE, Bijl M, Petri MA, et al. The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus. Arthritis Rheum (1998) 41:1813–8. doi:10.1002/1529-0131(199810)41: 10<1813::AID-ART13>3.3.CO;2-Y
- 103. Nieto A, Cáliz R, Pascual M, Matarán L, García S, Martín J. Involvement of Fcγ receptor IIIA genotypes in susceptibility to rheumatoid arthritis. *Arthritis Rheum* (2000) **43**:735–9. doi:10.1002/1529-0131(200004)43:4<735::AID-ANR3>3.0.CO;2-Q
- 104. Edberg JC, Langefeld CD, Wu J, Moser KL, Kaufman KM, Kelly J, et al. Genetic linkage and association of Fcγ receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. *Arthritis Rheum* (2002) 46:2132–40. doi:10.1002/art.10438
- 105. van Sorge NM, van der Pol WL, Jansen MD, Geleijns KPW, Kalmijn S, Hughes RAC, et al. Severity of Guillain-Barré syndrome is associated with Fcγ receptor III polymorphisms. *J Neuroimmunol* (2005) **162**:157–64. doi:10.1016/j. jneuroim.2005.01.016
- 106. Morgan AW, Griffiths B, Ponchel F, Montague BMN, Ali M, Gardner PP, et al. Fcγ receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. Arthritis Rheum (2000) 43:2328–34. doi:10.1002/1529-0131(200010)43:10<2328::AID-ANR21>3.0.CO;2-Z
- 107. Lee YH, Ji JD, Song GG. Associations between FCGR3A polymorphisms and susceptibility to rheumatoid arthritis: a meta analysis. J Rheumatol (2008) 35:2129–35. doi:10.3899/jrheum.080186
- 108. Bronner IM, Hoogendijk JE, De Visser M, van de Vlekkert J, Badrising UA, Wintzen AR, et al. Association of the leukocyte immunoglobulin G (Fcγ) receptor IIIa-158V/F polymorphism with inflammatory myopathies in Dutch patients. *Tissue Antigens* (2009) **73**:586–9. doi:10.1111/j.1399-0039. 2009.01236.x
- 109. Thabet MM, Huizinga TWJ, Marques RB, Stoeken-Rijsbergen G, Bakker AM, Kurreeman FA, et al. Contribution of Fcγ receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis. *Ann Rheum Dis* (2009) **68**:1775–80. doi:10.1136/ard.2008.099309
- 110. Zhou X-J, Lv J-C, Bu D-F, Yu L, Yang Y-R, Zhao J, et al. Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. *Int Immunol* (2010) 22:45–51. doi:10.1093/intimm/dxp113
- 111. Hatta Y, Tsuchiya N, Ohashi J, Matsushita M, Fujiwara K, Hagiwara K, et al. Association of Fc gamma receptor IIIB, but not of Fc gamma receptor IIA and IIIA polymorphisms with systemic lupus erythematosus in Japanese. *Genes Immun* (1999) 1:53–60. doi:10.1038/sj.gene.6363639
- 112. Tse WY, Abadeh S, Jefferis R, Savage CO, Adu D. Neutrophil FcgammaRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody

(ANCA)-positive systemic vasculitis. *Clin Exp Immunol* (2000) **119**:574–7. doi:10.1046/j.1365-2249.2000.01182.x

- 113. Xu G, He Q, Shou Z, Wang H, Zhang X, Wang Y, et al. NA1/NA2 heterozygote of Fcgr3b is a risk factor for progression of IgA nephropathy in Chinese. *J Clin Lab Anal* (2007) 21:298–302. doi:10.1002/jcla.20189
- 114. Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, Smith J, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. *Nature* (2006) 439:851–5. doi:10.1038/nature04489
- 115. Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, Kamesh L, et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. *Nat Genet* (2007) **39**:721–3. doi:10.1038/ng2046
- 116. Bournazos S, Bournazou I, Murchison JT, Wallace WA, McFarlane P, Hirani N, et al. Copy number variation of <i>FCGR3B</i> is associated with susceptibility to idiopathic pulmonary fibrosis. *Respiration* (2011) 81:142–9. doi:10.1159/000321997
- 117. Graf SW, Lester S, Nossent JC, Hill CL, Proudman SM, Lee A, et al. Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis. *Arthritis Res Ther* (2012) **14**:R28. doi:10.1186/ar3731
- 118. McKinney C, Broen JCA, Vonk MC, Beretta L, Hesselstrand R, Hunzelmann N, et al. Evidence that deletion at FCGR3B is a risk factor for systemic sclerosis. *Genes Immun* (2012) 13:458–60. doi:10.1038/gene.2012.15
- 119. Smith P, Dilillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. *Proc Natl Acad Sci U S A* (2012) **109**(16):6181–6. doi:10.1073/pnas.1203954109
- 120. Guyre PM, Graziano RF, Goldstein J, Wallace PK, Morganelli PM, Wardwell K, et al. Increased potency of Fc-receptor-targeted antigens. *Cancer Immunol Immunother* (1997) 45:146–8. doi:10.1007/s002620050418
- 121. Keler T, Guyre PM, Vitale LA, Sundarapandiyan K, van de Winkel JG, Deo YM, et al. Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J Immunol (2000) 165:6738–42. doi:10.4049/jimmunol.165.12.6738
- Heijnen IA, van de Winkel JG. A human Fc gamma RI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeutics. *J Hematother* (1995) 4:351–6. doi:10.1089/scd.1.1995.4.351
- 123. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. *Cancer Res* (2007) 67:8882–90. doi:10.1158/0008-5472. CAN-07-0696
- 124. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. *Cancer Res* (2010) **70**:4481–9. doi:10.1158/0008-5472.CAN-09-3704
- 125. Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. *Clin Cancer Res* (2013) **19**:1126–38. doi:10.1158/1078-0432.CCR-12-0989
- 126. Kim JM, Ashkenazi A. Fcgamma receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. J Exp Med (2013) 210:1647–51. doi:10.1084/jem.20131625
- 127. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol (2013) 6:1. doi:10.1186/1756-8722-6-1
- Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. *Immunity* (1995) 3:21–6. doi:10.1016/1074-7613(95)90155-8
- 129. McKenzie SE, Taylor SM, Malladi P, Yuhan H, Cassel DL, Chien P, et al. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. *J Immunol* (1999) **162**:4311–8.
- 130. Taylor SM, Reilly MP, Schreiber AD, Chien P, Tuckosh JR, McKenzie SE. Thrombosis and shock induced by activating antiplatelet antibodies in human Fc gamma RIIA transgenic mice: the interplay among antibody, spleen, and Fc receptor. *Blood* (2000) **96**:4254–60.
- 131. Reilly MP, Taylor SM, Hartman NK, Arepally GM, Sachais BS, Cines DB, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. *Blood* (2001) **98**:2442–7. doi:10.1182/blood.V98.8.2442

- 132. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. *Blood* (2006) **107**:2346–53. doi:10.1182/blood-2005-08-3122
- 133. Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost (2009) 7:171–81. doi:10.1111/j. 1538-7836.2008.03212.x
- 134. Robles-Carrillo L, Meyer T, Hatfield M, Desai H, Davila M, Langer F, et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. *J Immunol* (2010) **185**:1577–83. doi:10.4049/jimmunol.0903888
- 135. Stolla M, Stefanini L, Andre P, Ouellette TD, Reilly MP, McKenzie SE, et al. CalDAG-GEFI deficiency protects mice in a novel model of Fcgamma RIIAmediated thrombosis and thrombocytopenia. *Blood* (2011) **118**:1113–20. doi:10.1182/blood-2011-03-342352
- 136. Jönsson F, Mancardi DA, Zhao W, Kita Y, Iannascoli B, Khun H, et al. Human FcgammaRIIA induces anaphylactic and allergic reactions. *Blood* (2012) 119:2533–44. doi:10.1182/blood-2011-07-367334
- 137. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. *Int Immunol* (2006) 18:1759–69. doi:10.1093/intimm/ dxl110
- 138. Mancardi DA, Jonsson F, Iannascoli B, Khun H, van Rooijen N, Huerre M, et al. The murine high-affinity IgG receptor Fc(gamma)RIV is sufficient for autoantibody-induced arthritis. *J Immunol* (2011) 186:1899–903. doi:10.4049/jimmunol.1003642
- 139. Christianson GJ, Blankenburg RL, Duffy TM, Panka D, Roths JB, Marshak-Rothstein A, et al. beta2-microglobulin dependence of the lupus-like autoimmune syndrome of MRL-lpr mice. *J Immunol* (1996) **156**:4932–9.
- 140. Tan Sardjono C, Mottram PL, van de Velde NC, Powell MS, Power D, Slocombe RF, et al. Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcgamma receptor IIatransgenic mice. *Arthritis Rheum* (2005) **52**:3220–9. doi:10.1002/art.21344
- 141. van de Velde NC, Mottram PL, Powell MS, Lim B, Holmdahl R, Hogarth PM. Transgenic mice expressing human FcgammaRIIa have enhanced sensitivity to induced autoimmune arthritis as well as elevated Th17 cells. *Immunol Lett* (2010) **130**:82–8. doi:10.1016/j.imlet.2009.12.005
- 142. Tsuboi N, Ernandez T, Li X, Nishi H, Cullere X, Mekala D, et al. Regulation of human neutrophil Fcgamma receptor IIa by C5a receptor promotes inflammatory arthritis in mice. *Arthritis Rheum* (2011) **63**:467–78. doi:10.1002/ art.30141
- 143. Pietersz GA, Mottram PL, van de Velde NC, Sardjono CT, Esparon S, Ramsland PA, et al. Inhibition of destructive autoimmune arthritis in FcgammaRIIa transgenic mice by small chemical entities. *Immunol Cell Biol* (2009) 87:3–12. doi:10.1038/icb.2008.82
- 144. van Vuuren AJ, van Roon JA, Walraven V, Stuij I, Harmsen MC, McLaughlin PM, et al. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. *J Immunol* (2006) **176**:5833–8. doi:10.4049/jimmunol.176.10.5833
- 145. Thepen T, van Vuuren AJ, Kiekens RC, Damen CA, Vooijs WC, van de Winkel JG. Resolution of cutaneous inflammation after local elimination of macrophages. *Nat Biotechnol* (2000) 18:48–51. doi:10.1038/71908

- 146. Chen K, Nishi H, Travers R, Tsuboi N, Martinod K, Wagner DD, et al. Endocytosis of soluble immune complexes leads to their clearance by FcgammaRIIIB but induces neutrophil extracellular traps via FcgammaRIIA in vivo. *Blood* (2012) **120**:4421–31. doi:10.1182/blood-2011-12-401133
- 147. van Vugt MJ, Heijnen AF, Capel PJ, Park SY, Ra C, Saito T, et al. FcR gammachain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. *Blood* (1996) **87**:3593–9.
- 148. van Royen-Kerkhof A, Sanders EA, Walraven V, Voorhorst-Ogink M, Saeland E, Teeling JL, et al. A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcgammaRIIA transgenic mice. Br J Haematol (2005) 130:130–7. doi:10.1111/j.1365-2141.2005.05571.x
- 149. Zhi H, Rauova L, Hayes V, Gao C, Boylan B, Newman DK, et al. Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo. *Blood* (2013) 121:1858–67. doi:10.1182/blood-2012-07-443325
- 150. Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, et al. Antibodymediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. *J Immunol* (2011) 186:4223–33. doi:10.4049/jimmunol.1003412
- 151. Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. *Science* (2011) 333:1030–4. doi:10.1126/science.1206954
- 152. Li F, Ravetch JV. Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo. *Proc Natl Acad Sci U S A* (2013) **110**:19501–6. doi:10.1073/pnas.1319502110
- 153. Li M, Wirthmueller U, Ravetch JV. Reconstitution of human Fc gamma RIII cell type specificity in transgenic mice. J Exp Med (1996) 183:1259–63. doi:10.1084/jem.183.3.1259
- 154. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. *J Immunol* (2003) **170**:3528–33. doi:10.4049/jimmunol.170.7.3528
- 155. Mezo AR, McDonnell KA, Hehir CA, Low SC, Palombella VJ, Stattel JM, et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. *Proc Natl Acad Sci U S A* (2008) **105**:2337–42. doi:10.1073/pnas.0708960105

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 11 March 2014; paper pending published: 29 March 2014; accepted: 14 May 2014; published online: 30 May 2014.

Citation: Gillis C, Gouel-Chéron A, Jönsson F and Bruhns P (2014) Contribution of human Fcy Rs to disease with evidence from human polymorphisms and transgenic animal studies. Front. Immunol. **5**:254. doi: 10.3389/fimmu.2014.00254

This article was submitted to Immunotherapies and Vaccines, a section of the journal Frontiers in Immunology.

Copyright © 2014 Gillis, Gouel-Chéron, Jönsson and Bruhns. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.